Valois presents 'Landmark' dose indicator in record time
In March 2003, the US Food and Drug Administration published guidelines requiring the pharmaceutical industry to incorporate dose counters in all pMDIs (pressurized metered-dose inhalers) used in new products intended for the US market. Valois, who had anticipated this and was working on a concept, accelerated its development of its solution, 'Landmark', making it available to the industry in less than 18 months.
In March 2003, the US Food and Drug Administration published guidelines requiring the pharmaceutical industry to incorporate dose counters in all pMDIs (pressurized metered-dose inhalers) used in new products intended for the US market. Valois, who had anticipated this and was working on a concept, accelerated its development of its solution, 'Landmark', making it available to the industry in less than 18 months.
Landmark can be incorporated in any type of pMDI, adapted to count up to 200 doses, and will indicate accurately the quantity remaining in the device using a digit and colour display system, thus providing patients with improved comfort and complete safety.
Landmark is arriving on what is a particularly buoyant pMDI market, representing a total of 500 million units a year.
As matters stand, dose counters are mandatory only in the US. However, with the pharmaceutical industry increasingly operating within a logic based on global markets, such development is expected to become standard within the European market.
Several drug products incorporating Landmark are already in product development phases, the first of which should be on the market within three years.